MA39406A1 - Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents
Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-prolineInfo
- Publication number
- MA39406A1 MA39406A1 MA39406A MA39406A MA39406A1 MA 39406 A1 MA39406 A1 MA 39406A1 MA 39406 A MA39406 A MA 39406A MA 39406 A MA39406 A MA 39406A MA 39406 A1 MA39406 A1 MA 39406A1
- Authority
- MA
- Morocco
- Prior art keywords
- bis
- hexanediyl
- dioxo
- prodrug
- proline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne le composé qu'est le (2r,2'r)-bis(((((tétrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)méthyl)1,1'-adipoylbis(pyrrolidine-2-carboxylate), des compositions pharmaceutiques en contenant et leur utilisation en vue du traitement de maladies ou de troubles dans lesquels la déplétion en composant p de l'amyloïde sérique (sap) serait bénéfique, cela comprenant l'amylose, la maladie d'alzheimer, le diabète de type 2 et l'arthrose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1407506.3A GB201407506D0 (en) | 2014-04-29 | 2014-04-29 | Novel compound |
PCT/EP2015/058998 WO2015165833A1 (fr) | 2014-04-29 | 2015-04-27 | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39406A1 true MA39406A1 (fr) | 2017-07-31 |
MA39406B1 MA39406B1 (fr) | 2018-04-30 |
Family
ID=50972033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39406A MA39406B1 (fr) | 2014-04-29 | 2015-04-27 | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline |
Country Status (26)
Country | Link |
---|---|
US (3) | US9701668B2 (fr) |
EP (1) | EP3137457B1 (fr) |
JP (1) | JP6445046B2 (fr) |
KR (1) | KR20160145617A (fr) |
CN (1) | CN106459016B (fr) |
AR (1) | AR100204A1 (fr) |
AU (1) | AU2015252184B2 (fr) |
BR (1) | BR112016025129A2 (fr) |
CA (1) | CA2947060C (fr) |
CL (1) | CL2016002721A1 (fr) |
CR (1) | CR20160508A (fr) |
DO (1) | DOP2016000292A (fr) |
EA (1) | EA032129B1 (fr) |
ES (1) | ES2731253T3 (fr) |
GB (1) | GB201407506D0 (fr) |
IL (2) | IL248249A0 (fr) |
MA (1) | MA39406B1 (fr) |
MX (1) | MX2016014246A (fr) |
MY (1) | MY191088A (fr) |
PE (1) | PE20161558A1 (fr) |
PH (1) | PH12016502006B1 (fr) |
SG (1) | SG11201608371RA (fr) |
TW (1) | TWI676624B (fr) |
UA (1) | UA119871C2 (fr) |
UY (1) | UY36098A (fr) |
WO (1) | WO2015165833A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
GB201518950D0 (en) * | 2015-10-27 | 2015-12-09 | Glaxosmithkline Ip Dev Ltd | Compound |
GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE224366T1 (de) | 1997-10-31 | 2002-10-15 | Hoffmann La Roche | D-prolinderivate |
US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
BRPI0410936A (pt) | 2003-06-05 | 2006-06-27 | Pfizer Prod Inc | pró-fármaco inibidor da beta-lactamase |
GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
CA2604206A1 (fr) | 2005-04-12 | 2006-10-19 | Meiji Seika Kaisha, Ltd. | Derives de carbapenem substitues par 2-thioethenyle |
GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
-
2014
- 2014-04-29 GB GBGB1407506.3A patent/GB201407506D0/en not_active Ceased
-
2015
- 2015-04-27 BR BR112016025129A patent/BR112016025129A2/pt not_active Application Discontinuation
- 2015-04-27 CA CA2947060A patent/CA2947060C/fr active Active
- 2015-04-27 UA UAA201612105A patent/UA119871C2/uk unknown
- 2015-04-27 MY MYPI2016703952A patent/MY191088A/en unknown
- 2015-04-27 EP EP15720312.6A patent/EP3137457B1/fr active Active
- 2015-04-27 ES ES15720312T patent/ES2731253T3/es active Active
- 2015-04-27 TW TW104113338A patent/TWI676624B/zh not_active IP Right Cessation
- 2015-04-27 CR CR20160508A patent/CR20160508A/es unknown
- 2015-04-27 KR KR1020167029703A patent/KR20160145617A/ko not_active Application Discontinuation
- 2015-04-27 AR ARP150101262A patent/AR100204A1/es active IP Right Grant
- 2015-04-27 UY UY0001036098A patent/UY36098A/es not_active Application Discontinuation
- 2015-04-27 SG SG11201608371RA patent/SG11201608371RA/en unknown
- 2015-04-27 WO PCT/EP2015/058998 patent/WO2015165833A1/fr active Application Filing
- 2015-04-27 MX MX2016014246A patent/MX2016014246A/es active IP Right Grant
- 2015-04-27 EA EA201692185A patent/EA032129B1/ru not_active IP Right Cessation
- 2015-04-27 JP JP2016565212A patent/JP6445046B2/ja active Active
- 2015-04-27 PE PE2016001934A patent/PE20161558A1/es unknown
- 2015-04-27 AU AU2015252184A patent/AU2015252184B2/en active Active
- 2015-04-27 US US14/787,608 patent/US9701668B2/en active Active
- 2015-04-27 MA MA39406A patent/MA39406B1/fr unknown
- 2015-04-27 CN CN201580023347.0A patent/CN106459016B/zh not_active Expired - Fee Related
-
2016
- 2016-10-09 IL IL248249A patent/IL248249A0/en active IP Right Grant
- 2016-10-10 PH PH12016502006A patent/PH12016502006B1/en unknown
- 2016-10-26 CL CL2016002721A patent/CL2016002721A1/es unknown
- 2016-10-28 DO DO2016000292A patent/DOP2016000292A/es unknown
-
2017
- 2017-06-01 US US15/610,984 patent/US9873686B2/en active Active
- 2017-12-11 US US15/837,297 patent/US10597385B2/en active Active
-
2020
- 2020-12-01 IL IL279120A patent/IL279120A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
UA113186C2 (xx) | Макроциклічні інгібітори lrrk2 кінази | |
EA200802204A1 (ru) | Применение ингибиторов dpp iv | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
MA43113B1 (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
BR112014015630A2 (pt) | fluorometil-5,6-di-hidro-4h-[1,3]oxazinas | |
MA39146A1 (fr) | Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma | |
EA201590066A1 (ru) | Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1 | |
EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
MA39406A1 (fr) | Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
BR112017015474A2 (pt) | inibidores de bace1 | |
BR112016007430A2 (pt) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
MA46778B1 (fr) | Composition intranasale comprenant de la bétahistine | |
EA201990550A1 (ru) | Офтальмологический препарат, включающий азоловое соединение | |
MA46415A (fr) | Complexe et compositions pour le traitement de maladies ophtalmiques et dermatologiques | |
MA38487A1 (fr) | Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age) | |
BR112018008582A2 (pt) | derivados de d-prolina como agentes de eliminação de sap | |
EA201690788A1 (ru) | Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат | |
FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives | |
MA39188A1 (fr) | Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci | |
TH168999A (th) | สารยับยั้งของ rorc2 ประเภทเฮเทอโรไบไซโคลแอริล และวิธีการใช้ของมัน |